These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29153137)

  • 1. CKD stage V in AL amyloidosis: is it too late to treat? Maybe not.
    Leung N
    Kidney Int; 2017 Dec; 92(6):1321-1322. PubMed ID: 29153137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.
    Rezk T; Lachmann HJ; Fontana M; Sachchithanantham S; Mahmood S; Petrie A; Whelan CJ; Pinney JH; Foard D; Lane T; Youngstein T; Wechalekar AD; Bass P; Hawkins PN; Gillmore JD
    Kidney Int; 2017 Dec; 92(6):1476-1483. PubMed ID: 28729034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved outcomes for kidney transplantation in AL amyloidosis: impact on practice.
    Nuvolone M; Merlini G
    Kidney Int; 2019 Feb; 95(2):258-260. PubMed ID: 30665564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
    Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
    Badar T; D'Souza A; Hari P
    F1000Res; 2018; 7():. PubMed ID: 30228867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal Involvement in Systemic Amyloidosis Caused by Monoclonal Immunoglobulins.
    Karam S; Leung N
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1069-1079. PubMed ID: 33099424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Serum Ig Free Light Chains with Mortality and ESRD among Patients with Nondialysis-Dependent CKD.
    Ritchie J; Assi LK; Burmeister A; Hoefield R; Cockwell P; Kalra PA
    Clin J Am Soc Nephrol; 2015 May; 10(5):740-9. PubMed ID: 25825483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy-and light-chain amyloidosis.
    Safadi S; Saad A; Quint PS; Sethi S; Leung N; Kurtin P; Nasr SH
    Nephrol Dial Transplant; 2015 Jul; 30(7):1151-5. PubMed ID: 25796445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
    Comenzo RL
    Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis.
    Klimtchuk ES; Prokaeva TB; Spencer BH; Gursky O; Connors LH
    Amyloid; 2017 Jun; 24(2):115-122. PubMed ID: 28632419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin Light Chain Amyloidosis with Severe Liver Dysfunction Accompanied by Factor X Deficiency.
    Guo YM; Takahashi N; Miyabe K; Yoshida M; Abe F; Yamashita T; Nara M; Yoshioka T; Ohashi K; Goto A; Takahashi N
    Intern Med; 2019 Oct; 58(20):3039-3043. PubMed ID: 31243220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
    Zhang C; Huang X; Li J
    Blood Rev; 2017 Jul; 31(4):261-270. PubMed ID: 28336182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kidney and liver involvement in monoclonal light chain disorders.
    Pozzi C; Locatelli F
    Semin Nephrol; 2002 Jul; 22(4):319-30. PubMed ID: 12118397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical study of immunoglobulin light chain amyloidosis with antibodies to the immunoglobulin light chain variable region.
    Hoshii Y; Kiyama M; Cui D; Kawano H; Ishihara T
    Pathol Int; 2006 Jun; 56(6):324-30. PubMed ID: 16704496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal risk and response in amyloidosis.
    Dispenzieri A
    Blood; 2014 Oct; 124(15):2315-6. PubMed ID: 25301329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of chronic kidney disease in a patient with AL amyloidosis: A case report
.
    Rowland TA; Gillmore J; Bhandari S
    Clin Nephrol; 2019 May; 91(5):317-320. PubMed ID: 30935458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current diagnosis and treatment of AL amyloidosis in Japan: a nationwide epidemiological survey].
    Shimazaki C
    Rinsho Ketsueki; 2019; 60(8):973-978. PubMed ID: 31484898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels.
    Qiu Y; Zhang CL; Shen KN; Su W; Feng J; Zhang L; Cao XX; Li J
    Ann Hematol; 2018 Dec; 97(12):2465-2470. PubMed ID: 30056579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney.
    Eirin A; Irazabal MV; Gertz MA; Dispenzieri A; Lacy MQ; Kumar S; Sethi S; Nasr SH; Cornell LD; Fidler ME; Fervenza FC; Leung N
    Nephrol Dial Transplant; 2012 Mar; 27(3):1097-101. PubMed ID: 22067518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience.
    Ozawa M; Komatsuda A; Ohtani H; Nara M; Sato R; Togashi M; Takahashi N; Wakui H
    Clin Exp Nephrol; 2017 Apr; 21(2):212-227. PubMed ID: 27116248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.